CLINICAL TRIALS PROFILE FOR PROBUPHINE
✉ Email this page to a colleague
All Clinical Trials for probuphine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00447564 ↗ | Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence | Completed | Titan Pharmaceuticals | Phase 3 | 2006-10-01 | Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. |
| NCT00630201 ↗ | Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence | Completed | Titan Pharmaceuticals | Phase 3 | 2007-10-01 | Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patient with opioid dependence. Patients who have completed 24 weeks of treatment in the Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence, will be re-treated with Probuphine over an additional 24 weeks. |
| NCT00768482 ↗ | A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence | Terminated | Titan Pharmaceuticals | Phase 3 | 2008-09-01 | This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants). |
| NCT00772785 ↗ | Study of Probuphine in Patients With Opioid Dependence | Terminated | Titan Pharmaceuticals | Phase 3 | 2008-09-01 | Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks. |
| NCT01114308 ↗ | A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction | Completed | National Institute on Drug Abuse (NIDA) | Phase 3 | 2010-04-01 | Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for probuphine
Condition Name
Clinical Trial Locations for probuphine
Trials by Country
Clinical Trial Progress for probuphine
Clinical Trial Phase
Clinical Trial Sponsors for probuphine
Sponsor Name
